Biotech Archives - Page 73 of 795

2 minute read

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck’s Pneumococcal Shots – Analyst Says

April 10, 2:42 PM

The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte's advanced conjugate capabilities present a competitive advantage.

MRK

2 minute read

Cartesian Therapeutics’ Rare Disease Candidate Shows Long Lasting Benefit Over Argenx’s Vyvgart, Analyst Initiates With Buy

By Vandana Singh

April 10, 2:34 PM

Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current standards. Analysts project substantial market capture and peak sales potential.

ARGX

3 minute read

Aprea Therapeutics Announces Presentations On Its Next Generation WEE1 Inhibitor, APR-1051, And A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024

By Benzinga Newsdesk

April 10, 12:02 PM

Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been

APRE

2 minute read

Germfree And Orgenesis Announce Asset Purchase And Strategic Partnership Intended To Revolutionize Cell And Gene Therapy Through Decentralized Production And Global Accessibility

By Benzinga Newsdesk

April 10, 12:01 PM

Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (NASDAQ:ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an asset purchase and

ORGS

1 minute read

Kill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio’s Preclinical Candidate Shows Potential

By Vandana Singh

April 10, 10:38 AM

IN8bio's nsCAR platform, INB-300. Presented at AACR 2024, new preclinical data highlights its superior selectivity in targeting leukemia cells while sparing healthy tissue. Experience a potential wider therapeutic window without compromising efficacy.

INAB

2 minute read

Why Is European Healthcare Tech Giant Philips Stock Trading Higher On Wednesday?

By Vandana Singh

April 10, 9:47 AM

Philips has finalized an agreement with US authorities and the FDA regarding the recall of Respironics ventilators. Consent decree mandates remediation prioritization and operational focus in the US. Business outlook and financial guidance remain stable.

PHG

5 minute read

Aptevo Therapeutics Announces Advancements In Clinical Programs And One Preclinical Program

By Benzinga Newsdesk

April 10, 9:09 AM

Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now successfully transitioned to a higher dose level, accessing the potential for

APVO

3 minute read

Neuronetics, Inc. Announces New Publication In Brain Stimulation Confirms Full TMS Treatment Course Is Vital

By Benzinga Newsdesk

April 10, 8:39 AM

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders,

STIM

1 minute read

Palisade Bio Presents Development Overview Of PALI-2108 At The IBD Innovate: Product Development For Crohn’s & Colitis April 9-10, 2024 In Cambridge, MA

By Benzinga Newsdesk

April 10, 8:16 AM

– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year endCarlsbad, CA, April 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio,

PALI

2 minute read

Silo Pharma Set To Acquire Exclusive Licensing For Promising Alzheimer’s Disease Therapeutic; SPC-14 Shows Cognitive And Stress Reduction Benefits In Preclinical Models

By Benzinga Newsdesk

April 10, 8:11 AM

SPC-14 shows cognitive and stress reduction benefits in preclinical models SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage

SILO